Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.
You may also be interested in...
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Tasigna sales were up by almost 100% in one quarter with first-line clearance.
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Tasigna sales were up by almost 100% in one quarter with first-line clearance.
Tasigna Beats Sprycel To First-Line CML Punch
Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)